

Casual Friday Series

Spotting CVD on Bloodwork

A BIOGENETIX CLINICAL PRESENTATION
biogenetix.com





National Library of Medicine

National Center for Biotechnology Information

Cardiovascular diseases (CVD) remain among the 2 leading causes of death in the United States since 1975 with 633,842 deaths or 1 in every 4 deaths, heart disease occupied the leading cause of death in 2015 followed by 595,930 deaths related to cancer.^[2] CVD is also the number 1 cause of death globally with an estimated 17.7 million deaths in 2015, according to the World Health Organization (WHO). The burden of CVD further extends as it is considered the most costly disease even ahead of Alzheimer disease and diabetes with calculated indirect costs of \$237 billion dollars per year and a projected increased to \$368 billion by 2035.^[20]

Although the age-adjusted rate and acute mortality from MI have been declining over time, reflecting the progress in diagnosis and treatment during the last couple of decades, the risk of heart disease remains high with a calculated 50% risk by age 45 in the general population.^{[7][21]} The incidence significantly increases with age with some variations between genders as the incidence is higher in men at younger ages.^[2] The difference in incidence narrows progressively in the post-menopausal state.^[2]



National Library of Medicine

National Center for Biotechnology Information

Atherosclerosis is the pathogenic process in the arteries and the aorta that can potentially cause disease as a consequence of decreased or absent blood flow from stenosis of the blood vessels.[22]

It involves multiple factors dyslipidemia, immunologic phenomena, inflammation, and endothelial dysfunction. These factors are believed to trigger the formation of fatty streak, which is the hallmark in the development of the atherosclerotic plaque[23]; a progressive process that may occur as early as in the childhood.[24] This process comprises intimal thickening with subsequent accumulation of lipid-laden macrophages (foam cells) and extracellular matrix, followed by aggregation and proliferation of smooth muscle cells constituting the formation of the atheroma plaque.[25] As this lesions continue to expand, apoptosis of the deep layers can occur, precipitating further macrophage recruitment that can become calcified and transition to atherosclerotic plaques.[26]

Other mechanisms like arterial remodeling and intra-plaque hemorrhage play an important role in the delay and accelerated the progression of atherosclerotic CVD but are beyond the purpose of this article.[27]




Cardiovascular disease generally refers to 4 general entities: CAD, CVD, PVD, and aortic atherosclerosis.

CVD is the main cause of death globally.

Measures aimed to prevent the progression of atherosclerosis are the hallmark for primary prevention of CVD.

Risk factor and lifestyle modification are paramount in the prevention of CVD.



The Case:

60 Year old female

Dizziness

Stiffness

Muscle spasms

Left sided pain

Arthritis

Numbness

Upper back pain

Family hx:

Heart disease c/ HA (mother)

Chest pain (mother)

Stroke (mother)

Depression (mother)

BP: 159/85

184lbs

Drugs:

Tylenol

Gabapentin

Atorvastatin 80mg

Allopurinol 100mg

Fosamax

Bisoprolol 25mg

Lisinopril 10mg

Omeprazole 40mg

Escitalapram 10mg

Ropinirole 1mg



Biogenetix™

Test Result Released: Yes (seen)

Component	1/13/25 0734	7/3/24 0728	1/4/24 0800
Ref Range & Units			
Sodium	141	142	135 ▾
136 - 145 mmol/L			
Potassium	4.5	3.9	3.9
3.5 - 5.1 mmol/L			
Chloride	103	102	97 ▾
98 - 107 mmol/L			
CO2	27	30 ▲	28
22 - 29 mmol/L			
Anion Gap	11.0	10.0	10.0
8.0 - 16.0 mmol/L			
Glucose	103 ▲	107 ▲ CM	105 ▲ CM
65 - 99 mg/dL			

Comment: The American Diabetes Association has developed the following interpretive guidelines:

Fasting Glucose

Normal: 65-99 mg/dL

Impaired: 100-125 mg/dL

Possible Diabetes: > 125 mg/dL

Random Glucose

Possible Diabetes: ≥ 200 mg/dL

BUN	23 ▲	14	23 ▲
6 - 20 mg/dL			
Creatinine	0.89	0.84	0.79
0.50 - 0.90 mg/dL			
BUN/Creatinine Ratio	26 ▲	17	29 ▲
10 - 20			
Total Protein	7.6	7.4	7.6
6.6 - 8.7 g/dL			



Biogenetix

Alkaline Phosphatase	86	63	77
35 - 105 U/L			
AST	38 ^	29	32 R
0 - 33 U/L			
ALT	27	21	25 R
0 - 35 U/L			
CK	257 ^	227 ^	87
20 - 180 U/L			
Iron	117	53	91
37 - 145 ug/dL			
Cholesterol, Total	283 ^	250 ^ CM	254 ^ CM
0 - 199 mg/dL			
Comment: Desirable:	<200 mg/dL		
Borderline High:	200-240 mg/dL		
High:	>240 mg/dL		
Triglycerides	331 ^	351 ^ CM	295 ^ CM
0 - 149 mg/dL			
Comment: Triglycerides			
<150 mg/dL	Optimal		
150-199 mg/dL	Borderline High		
200-499 mg/dL	High		
>500 mg/dL	Very High		
HDL	84 ^	72 ^	50
40 - 60 mg/dL			
LDL Direct	152 ^	126 ^ CM	153 ^ CM
0 - 99 mg/dL			
Comment:			

GGT	133 ^	77 ^	58 ^
0 - 39 U/L			
LD	292 ^	216	213
0 - 250 U/L			
Magnesium	1.9	1.6	1.8 R
1.6 - 2.4 mg/dL			
Uric Acid	5.0	5.9 ^	5.9 ^
2.4 - 5.7 mg/dL			
TSH	2.72	3.43	2.57
0.27 - 4.20 uIU/mL			

Component Ref Range & Units	1/13/25 0734	1/4/24 0800	10/25/23 1039
WBC 4.40 - 10.40 th/uL	6.67	6.13	8.91
RBC 4.04 - 5.48 mi/uL	3.07▼	3.67▼	3.31▼
Hemoglobin 12.2 - 16.2 g/dL	11.6▼	11.2▼	10.5▼
Hematocrit 37.7 - 47.9 %	34.3▼	34.8▼	32.7▼
MCV 80.0 - 94.0 fl	111.7^	94.8^	98.8^
MCH 26.0 - 32.0 pg	37.8^	30.5	31.7
MCHC 32.0 - 36.0 g/dL	33.8	32.2	32.1
RDW 11.5 - 14.5 %	13.8	15.5^	12.0
RDW-SD 38.2 - 49.2 fl	56.5^	53.4^	43.8
Platelets 142 - 424 th/uL	337	258	317
Neutrophils Relative %	46.7	70.6	72.9
Immature Grans Relative %	0.7	0.5	0.3
Lymphocytes Relative %	41.4	20.9	18.6
Monocytes Relative %	9.4	5.5	6.8
Eosinophils Relative %	1.2	2.0	1.1
Basophils Relative %	0.6	0.5	0.3

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Iron Bind.Cap.(TIBC)	388		ug/dL	250-450
UIBC ⁰¹	326		ug/dL	131-425
Iron ⁰¹	62		ug/dL	27-159
▲ Ferritin ⁰¹	178 High		ng/mL	15-150

CBC With Differential/Platelet

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
WBC ⁰¹	6.2		x10E3/uL	3.4-10.8
▼ RBC ⁰¹	2.82 Low		x10E6/uL	3.77-5.28
Hemoglobin ⁰¹	11.2		g/dL	11.1-15.9
▼ Hematocrit ⁰¹	33.0 Low		%	34.0-46.6
▲ MCV ⁰¹	117 High		fL	79-97
▲ MCH ⁰¹	39.7 High		pg	26.6-33.0
MCHC ⁰¹	33.9		g/dL	31.5-35.7
RDW ⁰¹	12.8		%	11.7-15.4
Platelets ⁰¹	274		x10E3/uL	150-450
Neutrophils ⁰¹	60		%	Not Estab.
Lymphs ⁰¹	26		%	Not Estab.
Monocytes ⁰¹	10		%	Not Estab.
Eos ⁰¹	2		%	Not Estab.
Basos ⁰¹	1		%	Not Estab.
Neutrophils (Absolute) ⁰¹	3.8		x10E3/uL	1.4-7.0
Lymphs (Absolute) ⁰¹	1.6		x10E3/uL	0.7-3.1
Monocytes(Absolute) ⁰¹	0.6		x10E3/uL	0.1-0.9
Eos (Absolute) ⁰¹	0.1		x10E3/uL	0.0-0.4
Baso (Absolute) ⁰¹	0.0		x10E3/uL	0.0-0.2
Immature Granulocytes ⁰¹	1		%	Not Estab.
Immature Grans (Abs) ⁰¹	0.0		x10E3/uL	0.0-0.1

Test	Current Result and Flag		Previous Result and Date	Units	Reference Interval
▲ Glucose ⁰¹	112	High		mg/dL	70-99
BUN ⁰¹	16			mg/dL	8-27
Creatinine ⁰¹	0.68			mg/dL	0.57-1.00
eGFR	100			mL/min/1.73	>59
BUN/Creatinine Ratio	24				12-28
Sodium ⁰¹	139			mmol/L	134-144
Potassium ⁰¹	4.3			mmol/L	3.5-5.2
Chloride ⁰¹	99			mmol/L	96-106
Carbon Dioxide, Total ⁰¹	24			mmol/L	20-29
Calcium ⁰¹	9.6			mg/dL	8.7-10.3
Protein, Total ⁰¹	6.9			g/dL	6.0-8.5
Albumin ⁰¹	4.3			g/dL	3.8-4.9
Globulin, Total	2.6			g/dL	1.5-4.5
Bilirubin, Total ⁰¹	0.4			mg/dL	0.0-1.2
Alkaline Phosphatase ⁰¹	58			IU/L	44-121
AST (SGOT) ⁰¹	21			IU/L	0-40
ALT (SGPT) ⁰¹	15			IU/L	0-32

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Urinalysis Gross Exam ⁰¹				
Specific Gravity ⁰¹	1.022			1.005-1.030
pH ⁰¹	5.5			5.0-7.5
Urine-Color ⁰¹	Yellow			Yellow
Appearance ⁰¹	Clear			Clear
▶ WBC Esterase ⁰¹	2+ Abnormal			Negative
Protein ⁰¹	Negative			Negative/Trace
Glucose ⁰¹	Negative			Negative
Ketones ⁰¹	Negative			Negative
Occult Blood ⁰¹	Negative			Negative
Bilirubin ⁰¹	Negative			Negative
Urobilinogen, Semi-Qn ⁰¹	0.2		mg/dL	0.2-1.0
Nitrite, Urine ⁰¹	Negative			Negative
Microscopic Examination ⁰¹	See below: Microscopic was indicated and was performed.			
▶ WBC ⁰¹	11-30 Abnormal		/hpf	0-5
RBC ⁰¹	None seen		/hpf	0-2
Epithelial Cells (non renal) ⁰¹	0-10		/hpf	0-10
Casts ⁰¹	None seen		/lpf	None seen
▶ Bacteria ⁰¹	Moderate Abnormal			None seen/Few
Urinalysis Reflex ⁰¹	This specimen has reflexed to a Urine Culture.			
Urine Culture, Routine ⁰¹	Will Follow			

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Cholesterol, Total ⁰¹	181		mg/dL	100-199
Triglycerides ⁰¹	129		mg/dL	0-149
HDL Cholesterol ⁰¹	67		mg/dL	>39
VLDL Cholesterol Cal	22		mg/dL	5-40
LDL Chol Calc (NIH)	92		mg/dL	0-99
T. Chol/HDL Ratio	2.7		ratio	0.0-4.4
Please Note: ⁰¹				

T. Chol/HDL Ratio			
		Men	Women
1/2 Avg.Risk	3.4	3.3	
Avg.Risk	5.0	4.4	
2X Avg.Risk	9.6	7.1	
3X Avg.Risk	23.4	11.0	

Non-HDL Cholesterol	114		mg/dL	0-129
---------------------	-----	--	-------	-------

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
▼ Vitamin B12 ⁰¹	151 Low		pg/mL	232-1245

Magnesium

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
▼ Magnesium ⁰¹	1.5 Low		mg/dL	1.6-2.3

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
TSH ⁰¹	1.680		uIU/mL	0.450-4.500
Thyroxine (T4) ⁰¹	8.1		ug/dL	4.5-12.0
T3 Uptake ⁰¹	34		%	24-39
Free Thyroxine Index	2.8			1.2-4.9

Hgb A1c with eAG Estimation

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Hemoglobin A1c ⁰¹	4.9		%	4.8-5.6
Please Note: ⁰¹	Prediabetes: 5.7 - 6.4 Diabetes: >6.4 Glycemic control for adults with diabetes: <7.0			
Estim. Avg Glu (eAG)	94		mg/dL	

Vitamin D, 25-Hydroxy

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Vitamin D, 25-Hydroxy ⁰¹	54.7		ng/mL	30.0-100.0
Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2). 1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press. 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.				

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
▲ C-Reactive Protein, Cardiac ⁰¹	5.82 High		mg/L	0.00-3.00

Homocyst(e)ine

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
▲ Homocyst(e)ine ⁰¹	75.7 High Results confirmed on dilution.		umol/L	0.0-14.5

Phosphorus

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Phosphorus ⁰¹	3.4		mg/dL	3.0-4.3

LDH

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
▲ LDH ⁰¹	248 High		IU/L	119-226

GGT

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
GGT ⁰¹	39		IU/L	0-60

Triiodothyronine (T3)

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Triiodothyronine (T3) ⁰¹	115		ng/dL	71-180

Thyroid Antibodies

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Thyroid Peroxidase (TPO) Ab ⁰¹	12		IU/mL	0-34
Thyroglobulin Antibody ⁰¹	Will Follow			

Coronary Computed Tomography Angiography (CCTA)

A CCTA is a diagnostic test that produces detailed 3D images of the arteries in your heart to detect abnormalities in how blood flows through your heart and to diagnose cardiovascular disease. It is sometimes used to determine overall function of the heart. An abnormality of the arteries may include plaque buildup, which may consist of calcium, cholesterol or fat that can lead to cardiovascular diseases like [coronary artery disease](#) or [heart failure](#).

You may need a CCTA if you have symptoms of cardiovascular disease or if you are diagnosed and your doctor needs more information about your condition. Reasons for a CCTA may include:

- Abnormal test results (stress testing, [echocardiogram](#), [electrocardiogram](#))
- Abnormal coronary artery structure
- Risk for developing coronary artery disease
- New or worsening coronary artery disease symptoms
- You have undergone [coronary artery bypass graft \(CABG\) surgery](#).

A CCTA can also determine any type of heart disease, including heart structure or aortic abnormalities.




Fig. 7 CAD-RADS 4A/P1. Focal non-calcified plaque in the mid LAD (yellow arrow) with 70–99% severe coronary stenosis and mild amount of focal non-calcified plaque burden (P1) (left). Invasive coronary angiography confirming 70–99% stenosis in the mid LAD (yellow arrow, right). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Left Anterior Descending Coronary Artery -LAD



Reach out to your
Biogenetix Rep.



Submit your case
to the CC team



Biogenetix™